Nureca Ltd (NURECA) — shareholding pattern, promoter holding, financials and share price
About Nureca Ltd (NURECA)
Nureca Ltd operates in the Medical Equipment & Supplies industry, within the Healthcare sector. It trades on the NSE as NURECA and on the BSE under scrip code 543264. Its ISIN is INE0DSF01015.
Incorporated in 2016, Nureca Ltd is in the business of Home Healthcare and Wellness Products. [1]
Nureca Limited is a digital-first healthcare company with a focus on home diagnostics, wellness devices, and personal fitness equipment. Specializing in delivering a wide range of products through online platforms, Nureca demonstrates a significant shift towards digital sales with over 90% revenue contribution from online channels. The company boasts an impressive 27% YoY growth in GMV and has achieved a 50% YoY growth in revenue reflecting dynamic market penetration. They have introduced eight new products, reinforcing their commitment to innovation and product development. Moreover, their expanding in-house manufacturing capabilities further illustrate Nureca’s strategic intent to dominate the healthcare and wellness market.
Listed peers in Medical Equipment & Supplies: Yash Optics & Lens Ltd, Aprameya Engineering Ltd, Earkart Limited, QMS Medical Allied Services Ltd, Avience Biomedicals Ltd, Choksi Asia Ltd.
Valuation & Returns
10 Jul 2026At ₹233.9 a share on 10 Jul 2026, Nureca Ltd (NURECA) was valued at a price-to-earnings ratio of 107.3x against an industry P/E of 44.11x and a price-to-book of 1.15x on a book value of ₹203.61 per share as of Mar 2025. Solomo computes return on equity of 1.07% and return on capital employed of 3.15% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 107.3x
- Industry P/E
- 44.11x
- P/B
- 1.15x
- EPS (TTM)
- ₹2.18
- Book value / share
- ₹203.61
- ROE
- 1.07%
- ROCE
- 3.15%
- ROA
- 0.99%
- Debt / equity
- 0.03x
- Dividend yield
- 0%
- EBITDA margin
- 5.63%
- 52-week range
- ₹200.1 – ₹343.6
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Nureca Ltd (NURECA) reported revenue of ₹147 crore, net profit of ₹2 crore and earnings per share of ₹2.18. That compares with revenue of ₹110 crore and net profit of ₹1 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹35.41 crore and net profit ₹-6.09 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 256 | 111 | 92 | 110 | 147 |
| Net profit (₹ cr) | 45 | -8 | -2 | 1 | 2 |
| EPS (₹) | 44.96 | -8.25 | -1.79 | 0.85 | 2.18 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 169.24% | -7.15% | 9.57% | 34.01% |
| Profit growth | 120.14% | -63.61% | - | 144.71% |
| Stock price CAGR | - | -30% | -8% | 4% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 68.09% of Nureca Ltd (NURECA) (unchanged from the previous quarter), foreign institutional investors (FII) hold 0.11% and domestic institutional investors (DII) hold 0.24%. Market capitalisation was ₹223 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2021.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 68.09% | - | 0.11% | 0.24% | 31.91% |
| Mar 2026 | 68.09% | - | 0.28% | 0.24% | 31.91% |
| Dec 2025 | 64.97% | - | 0.08% | 0.04% | 35.03% |
| Sep 2025 | 64.97% | - | 0.07% | 0.04% | 35.03% |
| Jun 2025 | 64.33% | - | 0.07% | 0.04% | 35.67% |
| Mar 2025 | 64.3% | - | 1.07% | 0.04% | 35.7% |
| Dec 2024 | 64.06% | - | 0.36% | 0.04% | 35.94% |
| Sep 2024 | 63.77% | - | 0.69% | 0.04% | 36.23% |